PQIs

POSITIVE QUALITY INTERVENTIONS (PQIs)

NCODA’s PQIs are precise and concise peer-reviewed clinical guidance resources. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet simple-to-use resource to manage patients receiving oral or IV oncolytics.

BENEFITS OF PQIs

The treatment and management of oncology patients on oral drug therapy continues to change and evolve. This complexity means healthcare professionals need a quick resource for information about drug therapy management. 

NCODA’s PQIs are that resource. 

They foster better care for patients through appropriate patient identification, treatment selection, increased speed to therapy, reduced cost and hospitalization, and improved adherence techniques for the patient and their medically-integrated teams.

NCODA PQI Photo

Optimize Drug Therapy and Patient Outcomes

Positive Quality Interventions (PQIs), one of NCODA’s Quality Standards, are designed to standardize oncology practices and support positive clinical outcomes. We invite professionals from every sector of oncology to join the PQI Committee and contribute relevant topics to this growing body of knowledge. Together, we can better serve all patients living with cancer.

  • Demonstrating the benefits of MID to third-party payers
  • Providing CAWT data for insurance input
  • Quantifying the benefits of MID institutions

PQIs BY CATEGORY

Medication

Management of Abemaciclib (Verzenio®) Associated Diarrhea

Written by: Derek Gyori, PharmD and Julianne Orr, PharmD

Advanced Breast Cancer: Appropriate Patient Identification with Abemaciclib (Verzenio®)

Written by: Jan Montgomery, PharmD, South Carolina Oncology Associates and Jacob Dygert, South University School of Pharmacy

Acalabrutinib (Calquence®) in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Written by: Trey McNiel, PharmD, Georgia Cancer Specialists

Afatinib (Gilotrif®) Management for Non-Small Cell Lung Cancer

Written by: Chris Sellers, RPh, Texas Oncology

Management of Alpelisib (Piqray®) Induced Hyperglycemia

Written by: Natasha Khrystolubova, RPh, BCOP, Florida Cancer Specialists and Jody Agena, PharmD, Virginia Cancer Specialists

Avapritinib (Ayvakit®) Management for Advanced Systemic Mastocytosis

Written by: Andrew Kuykendall, MD; Katherine Tobon, PharmD, BCOP; Syeda Saba Kareem PharmD, BCOP

Avapritinib (Ayvakit®) Management for Gastrointestinal Stromal Tumor

Written by: Joshua Nubla, PharmD, NCODA

Use of Belumosudil (Rezurock®) for the Treatment of Chronic Graft-Versus-Host Disease

Written by: Megan Dillaman, PharmD, BCOP

Bortezomib (Velcade®) Management for Multiple Myeloma and Mantle Cell Lymphoma

Written by: Joshua Nubla, PharmD, NCODA

Brentuximab Vedotin (Adcetris®): Neuropathy and Neutropenia Management

Written by: Kirollos Hanna, PharmD, BCPS, BCOP, Mayo Clinic College of Medicine and M Health Fairview and Kayla Randle, PharmD, BCOP, Kaiser Permanente – Southwood Oncology Clinic

Cabazitaxel (Jevtana®) for Patients with Metastatic Castration-Resistant Prostate Cancer

Written by: Alyson Leonard, PharmD, BCPS, BCOP, Cone Health

CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

Written by: Ann Schwemm, PharmD, MPH, BCOP, University of Minnesota Health

Cemiplimab-rwlc (Libtayo®) Patient Management

Written by: Marko Skelin MPharm PhD, Assistant Professor, Faculty of Medicine, University of Rijeka

Luis Raez, MD, FACP, Memorial Cancer Institute/Memorial Health Care System

Copanlisib (Aliqopa™) for the Management of Relapsed/Refractory Follicular Lymphoma

Written by: Andrew Kowalski, PharmD, and Osama Abdelghany, PharmD, MHA, BCOP, Smilow Cancer Hospital at Yale New Haven Health 

Copanlisib (Aliqopa™) Toxicity Management

Written by: Lauren Held, PharmD, BCOP, Seattle Cancer Care Alliance

Daratumumab (Darzalex®) for Multiple Myeloma

Written by: Lauren Trisler, PharmD, BCOP, Carle Cancer Center

Darolutamide (Nubeqa®) in the Treatment of Non-Metastatic Castration Resistant Prostate Cancer

Written by: Michelle Phillips, PharmD, BCOP, Wilmot Cancer Center 

Liposomal Daunorubicin-Cytarabine (Vyxeos®) Management

Written by: Anna Howard, PharmD, BCOP, Billings Clinic

Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies

Written by: Yonatan Resnick, PharmD, New England Cancer Specialists

Durvalumab (Imfinzi®) Therapy Overview

Written by: Joshua Nubla, PharmD, NCODA

Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia and Follicular Lymphoma

Written by: Linda Frisk, PharmD, Ironwood Cancer and Research Centers

Enfortumab Vedotin (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma

Written by: Andrew Ruplin, PharmD, Seattle Cancer Care Alliance

Enzalutamide (Xtandi®) for patients with castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer

Written by: Samantha Larson, PharmD M Health Fairview

Stomatitis Prophylaxis During Everolimus (Afinitor®) Therapy

Written by: Matthew Schulz, RPh Rocky Mountain Cancer Centers

Fam-Trastuzumab deruxtecan-nxkiFam-Trastuzumab Deruxtecan-nxki (Enhertu®) Management

Written by: Brandy Persson, PharmD, BCPS, BCOP and Rebecca Fanning, PharmD, BCPS, Cone Health

Fostamatinib (Tavalisse®) Use In Chronic Immune Thrombocytopenia

Written by: Julianne Darling, PharmD, BCOP, Indiana University Health Simon Cancer Center

Written by: Bryan J. Brinda, PharmD, Indiana University Simon Cancer Center

Granisetron (Sancuso®) Transdermal System for Chemotherapy Induced Nausea and Vomiting

Written by: Latha Radhakrishnan, PharmD, BCPS, BCOP, University of Illinois Hospital and Health Sciences System

Ibrutinib (Imbruvica®) Expansion with Obinutuzumab (Gazyva®)

Written by: Tammy McClellan, PharmD, Riverside Healthcare

Ibrutinib (Imbruvica®) Management

Written by: Jody Agena, PharmD, MBA, BCOP

Management of Infigratinib (Truseltiq™) in Cholangiocarcinoma

Written by: Jane E. Rogers, Pharm.D., BCOP, U.T. M.D. Anderson Cancer Center

Isatuximab-irfc (Sarclisa®) In Patients with Relapsed Refractory Multiple Myeloma

Written by: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch

Ixazomib (Ninlaro®) In the Treatment of Multiple Myeloma

Written by: Kirollos Hanna, PharmD, BCPS, BCOP, University of Minnesota Medical Center & Mayo Clinic

Non-hormonal Birth Control Alternative with Lactic acid/Citric acid/Potassium Bitartrate (Phexxi®)

Written by: Natasha Olson, PharmD, NCODA

Larotrectinib (Vitrakvi®) Overview

Written by: Elizabeth Ledbetter, PharmD, Indiana University Health

Larotrectinib (Vitrakvi®) Genomic Testing Management

Written by: Joshua Nubla, PharmD, NCODA

Loncastuximab tesirine-lpyl (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma

Written by: Kelly Valla, PharmD, BCOP, Emory Healthcare Winship Cancer Institute

Lurbinectedin (Zepzelca) for Small Cell Lung Cancer

Written by: Luis E. Raez, MD, FACP

Mobocertinib (Exkivity™) Side Effect Management

Written by: Danny Nguyen, MD, Nishan Tchekmedyian, MD, André K.D. Liem, MD, City of Hope National Medical Center

Neratinib (Nerlynx®) Diarrhea Management

Written by: Eric Dallara, RPh, New England Cancer Specialist

Netupitant/Fosnetupitant and Palonosetron (Akynzeo®) for Chemotherapy-Induced Nausea and Vomiting

Written by: Doug Braun, PharmD and Emily Gallagher, PharmD | AON

Niraparib (Zejula): Dose Modifications Based on Weight and Platelet Counts

Written by: Michelle Phillips, PharmD, University of Rochester Medical Center

Obinutuzumab (Gazyva®) In Chronic Lymphocytic Leukemia and Follicular Lymphoma

Written by: Renee Shirakawa, PharmD, BCOP, USC – Norris Comprehensive Cancer Center

Olanzapine (Zyprexa®) In Chemotherapy Induced Nausea and Vomiting

Written by: Julianne Orr, PharmD, Indiana University Health Simon Cancer Center

Written by: Latha Radhakrishnan, PharmD, BCOP The University of Illinois Hospital and Health Sciences System

Written by: Katie Carter, PharmD, BCPS, Indiana University Health

Olaparib (Lynparza®) Expansion with Bevacizumab (Avastin®)

Written by: Ibrahim Ahsan, PharmD, BCPS, Tomah Health

Written by: Alyson Leonard, PharmD, BCPS, BCOP, Cone Health 

Pacritinib (Vonjo™) in Cytopenic Myelofibrosis

Written by: Sarah Rockwell, PharmD, BCOP, Moffitt Cancer Center

PARP Inhibitor for Ovarian Cancer

Written by: Martina Fraga, PharmD, Henry Ford Cancer Institute

Ponatinib (Iclusig®) Patient Management

Written by: Jessie Signorelli PharmD, BCOP, Massachusetts General Hospital

Pralsetinib (Gavreto®) Management for Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Written by: Kayla Randle, PharmD, BCOP Kaiser Permanente of Georgia

Use of Rasburicase (Elitek®) for Treatment of Tumor Lysis Syndrome

Written by: Marie C. Rush, PharmD, CPP, BCOP, Wake Forest Baptist Health

Regorafenib (Stivarga®) In the Treatment of Hepatocellular Carcinoma

Written by: Jody Agena, PharmD, Virginia Cancer Specialists

Regorafenib (Stivarga®) in Metastatic Colorectal Cancer

Written by: Neal Dave, PharmD, Texas Oncology; Natasha Khrystolubova, RPh, BCOP, Florida Cancer Specialists 

Ripretinib (Qinlock®) for Treatment of Adults with Advanced Gastrointestinal Stromal Tumors

Written by: Joseph Bubalo PharmD, Oregon Health & Science University

Ropeginterferon alfa-2b (BESREMi) Use in Polycythemia Vera

Written by: Amir Ali, PharmD, BCOP Keck Medicine of USC

Use of Rucaparib (Rubraca®) and Indications

Written by: Jon Suyko Pharm.D., BCPS, UCHealth Highlands Ranch

Radium Ra 223 Dichloride (Xofigo®) Management

Written by: Jill Boyett, PharmD, CPh, UF Health Jacksonville – Orange Park Oncology

Ruxolitinib (Jakafi®) – Managing Myelofibrosis Patients

Written by: Todd Murphree, PharmD, Clearview Cancer Institute

Ruxolitinib (Jakafi®): Managing Treatment of Polycythemia Vera

Written by: Neal Dave, PharmD, Texas Oncology 

Selinexor (Xpovio®) Patient Management

Written by: Jeremiah Moore, PharmD, University of Rochester Medical Center

Selpercatinib (Retevmo®) Management

Written by: Joshua Nubla, PharmD, NCODA

 

Selpercatinib (Retevmo®) Genomic Testing Management

Written by: Joshua Nubla, PharmD, NCODA

 

Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

Written by: Jeff Engle, PharmD, MS University of Minnesota Masonic Cancer Clinic

Tafasitamab (Monjuvi®) for Diffuse Large B-Cell Lymphoma

Written By: Jeff Engle, PharmD, MS, M Health Fairview University of Minnesota Medical Center

 

Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma 

Written by: Houston Holmes, MD, Texas Oncology

Telotristat Ethyl (Xermelo®) for the Management of Carcinoid Syndrome Diarrhea

Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology

Temozolomide (Temodar®) for Glioblastoma Multiforme

Written By: Hassaan Shaikh, PharmD & Emily Brugioni, MD University Health

Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

Written By: Paige Reid, PharmD, Texas Oncology

 

Tisotumab vedotin-tftv (Tivdak®) Management

Written By: Shraddha Kansagra, PharmD, BCOP, University of Texas Southwestern Medical Center

 

Tivozanib (Fotivda®) for Relapsed or Refractory Advanced Renal Cell Carcinoma

Written By: Pedro C. Barata, MD, Tulane University

 

Trifluridine and Tipiracil (Lonsurf®) for Treatment of Gastric Cancer

Written by: Isabel Houlzet, PharmD, BCPS, BCOP Miami Cancer Institute

Trifluridine and Tipiracil (Lonsurf®) for Metastatic Colorectal Cancer

Written by: Jennifer M. Hasiak O’Doherty, PharmD, Hematology Oncology Consultants, PC

Trilaciclib (Cosela™) Management

Written by: Autumn Alvarez, PharmD, BCPS, Blue Ridge Cancer Care

Tucatinib (Tukysa®) Management

Written by: Katie Carter, PharmD, BCPS, IU Simon Cancer Center

Chronic Lymphocytic Leukemia with Del17p and Venetoclax

Written by: Danny Olszta, PharmD, BCOP, Jolliet Oncology Hematology Associates 

Venetoclax (Venclexta®) for the Treatment of Acute Myeloid Leukemia

Written by: Alison Carulli, PharmD, BCOP, Hospital of the University of Pennsylvania

Venetoclax (Venclexta®) Risk Stratification, Dosing, and Dispensing Procedure

Written by: Jon Suyko, PharmD, BCPS, UCHealth Highlands Ranch

Zanubrutinib (Brukinsa®) Patient Selection and Management in Mantle Cell Lymphoma

Written by: Kayla Randle, PharmD, BCOP Kaiser Permanente Georgia Oncology

Supportive Care

Chemotherapy, Oncolytic, Antiemetic Induced Constipation

Written by: Brady Quinn and Britny Rogala, PharmD – University of Rhode Island College of Pharmacy

DPYD Testing Prior to Fluoropyrimidine Treatment

Written by: Dan Hertz, PharmD, PhD – University of Michigan College of Pharmacy

Managing EGFR Inhibitor Induced Rash

Written by: Sara Moran Smith, PharmD, BCOP, M Health Fairview

FGFR Inhibitor Side Effect Management

Written by: Julia Stevens, PharmD, BCOP and Emmeline Academia, PharmD, BCOP –  Beth Israel Deaconess Medical Center

Opioid Induced Constipation

Written by: Neal Dave, PharmD and Julianne Orr, PharmD – Texas Oncology and Indiana University

Oncolytic Induced Diarrhea

Written by: Joshua Nubla, PharmD, NCODA

Overview of Breast Cancer Survivorship

Written by: Tahsin Imam, PharmD, NCODA

Medication Induced Hand-Foot Syndrome

Written by: Jonas Congelli, RPh, Hematology Oncology Associates of CNY 

Chemotherapy-Induced Nausea and Vomiting

Written by: Kirollos S. Hanna, PharmD, BCPS, BCOP, University of Minnesota Medical Center & Mayo Clinic

Chemotherapy Induced Peripheral Neuropathy

Written by: Andrea Clarke, PharmD and Becky Fahrenbruch, PharmD, BCOP, University of Minnesota Health

Managing Immunotherapy Treatment Related Rash

Written by: Natasha Heimbigner, PharmD, Summit Cancer Centers

Managing TKI-Induced Hand-Foot Skin Reaction

Written by: Jessie Modlin, PharmD, BCOP St. Luke’s Cancer Institute 

Vaccination for Non-Transplant Patients with Cancer

Written by: Michelle Hoa and Natasha Heimbigner, PharmD, Summit Cancer Centers

VEGF Inhibitor-Induced Hypertension

Written by: Sarah Gillaspie, PharmD/MPH Candidate 2024 and Sarah Khaddage, PharmD Candidate 2023

Diseases

Advanced Systemic Mastocytosis Patient Diagnostic Algorithm

Written by: Prithviraj Bose, MD, UT MD Anderson Cancer Center

clonoSEQ Next Generation Sequencing for Minimum Residual Disease Testing in Chronic Lymphocytic Leukemia

Written by: Eileen Peng, PharmD, MS, Astera Cancer Care

Erythropoietin Stimulating Agent (ESA) Ineligibility in Myelodysplastic Syndromes (MDS)

Written by: Kayla Boyd, PharmD, BCOP Kaiser Permanente Georgia

Non-Small Cell Lung Cancer Stage III Overview and Patient Eligibility of Durvalumab (Imfinzi®)

Written by: Joshua Nubla, PharmD, NCODA

Patient Screening for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Written by: Tammy McClellan, PharmD, Riverside Healthcare

Proactive Symptom Management in Myelofibrosis

Written by: Kristyn DiSogra, PharmD, BCOP and Justin Arnall, PharmD, BCOP, Atrium Health

Want to author a PQI?

PQIs are created and written by NCODA members. If you have a relevant topic that highlights a specific aspect of cancer patient care, please contact us for consideration of authorship and incorporation into our library of best practices.

PQI Committee Members

Kirollos Hanna, PharmD, BCPS, BCOP | University of Minnesota Medical Center & Mayo Clinic, MN (Chief Editor)

Michelle Phillips, PharmD, BCOP | UR Specialty Pharmacy, NY (Chair)

Kayla Boyd, PharmD, BCOP | Kaiser Permanente, GA (Chair)

Jasmine Patel, PharmD, BCOP | Boston Medical Center, MA

Jen Hasiak, PharmD | Hematology & Oncology Consultants Pharmacy, NE

Jody Agena, PharmD, MBA, BCOP | Virginia Cancer Specialists, VA

Jon Suyko, PharmD | UC Health Highlands Ranch, CO

Lauren Trisler, PharmD | Florida Cancer Specialists, FL

Loan Lam, PharmD | The Polyclinic, WA

McKay Herpel, PharmD | Cleveland Clinic Specialty Pharmacy, OH

Raquel Rhone, PharmD | Texas Oncology, TX

Lawrence Garbo, MD | New York Oncology Hematology, NY (Physician Medical Reviewer)

Wayne Ormsby, MD | Utah Cancer Specialists, UT (Physician Medical Reviewer)

Natasha Olson, PharmD | NCODA, WA

Our committee members take an active role in their areas of expertise to better patient care in all aspects of the oncology spectrum. Interested in contributing?
Join a Committee →

PQI CORPORATE PARTNERS

RESOURCES

Cost Avoidance Waste Tracker

Positive Quality Interventions

PQI in Action

OCE Sheets

IVE Sheets

Treatment Support Kits

PQI Podcast

Members

Member Resources

OPTA

Committees

Member Login

Events

Webinars

Spring Forum

Oncology Institute

PSO Annual Meeting

Fall Summit

315-655-4640

P.O. Box 468
Cazenovia, NY 13035

NCODA is a 501(c)(3) Organization

error: